Low dose sirolimus for long COVID
Part of Infections, Lungs & breathing clinical trials.
This trial tests if a low dose of sirolimus, a medicine that calms the immune system, can help people with long COVID. If you have had long COVID symptoms for at least 6 months, like severe fatigue, brain fog, or chest pain, you may be able to join.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have had a confirmed or suspected COVID-19 infection at least 6 months ago.
- A doctor has diagnosed you with long COVID.
- You have at least one ongoing symptom such as headache, memory problems, trouble sleeping, mood changes, chest pain, heart palpitations, shortness of breath, cough, muscle or joint pain, or stomach issues.
- You have at least moderate fatigue and moderate post-exertional malaise (feeling much worse after activity).
- You can travel to New York City (5 East 98th Street) for all study visits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether antiviral drugs (Truvada and Selzentry) can help people with long COVID. You may qualify if you have had long COVID symptoms for at least 6 months, including fatigue and post-exertional malaise.
This study tests whether medicines that fight viruses (similar to those used for herpes or COVID) can reduce Long COVID symptoms like fatigue and brain fog. Researchers believe lingering viruses or viral reactivation may drive Long COVID, and this trial will see if antiviral drugs help.
This trial is testing treatments for people with long COVID, which is when symptoms last more than 3 months after a COVID-19 infection. The trial focuses on three specific symptom groups: heart inflammation, cough, or severe fatigue with signs of inflammation. It aims to find if certain immune-modulating therapies can help.
This trial tests a care program designed to help people who continue to have symptoms after recovering from COVID-19. It aims to prevent long-term health problems and improve well-being.
This trial studies how your immune system responds in people with Long COVID after a past COVID-19 infection. It may help researchers understand why symptoms linger and how the body’s response could be targeted.
This study tests whether a drug called pembrolizumab (a type of immunotherapy) can help people with ongoing neurological symptoms after COVID-19. The goal is to see if it is safe and possibly improves symptoms like brain fog, fatigue, and dizziness.
Hear when a new Long Covid-19 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.